Literature DB >> 2633925

Single and multiple dose pharmacokinetics of a new NSAID (droxicam) in healthy volunteers.

L Martinez1, J Sanchez, R Roser, J Garcia-Barbal, R Sagarra, A Bartlett.   

Abstract

The pharmacokinetics of droxicam, both as a single 10 mg dose and as a multidose regimen of 10 mg/day for 20 consecutive days, have been studied in healthy volunteers. The study was performed in two separate groups of volunteers. Following a single dose the Cmax was 0.82 +/- 0.15 micrograms/ml, the Tmax was achieved at 6.1 +/- 3.5 h, the elimination half life was 65.7 +/- 17.6 h, the Clt/F was 2.04 +/- 0.53 ml/min, the Vd/F was 11.0 +/- 1.7 l and the AUC infinity was 86.9 +/- 24.6 mugh/ml, which was similar to results reported in other study from piroxicam (10 mg). Following multiple doses the Cmed(ss) was 2.06 +/- 0.42 microgram/ml, the Tmax(ss) was 8.2 +/- 6.0 h, the elimination half life was 41.4 +/- 12.4 h, the Clt/F was 3.30 +/- 0.63 ml/min, the Vd/F was 11.8 +/- 4.3 l and the AUC infinity was 52.4 +/- 11.3 mugh/ml. The differences encountered between single and multiple dose administration in elimination kinetics are due to the wide interpersonal variation described for the elimination half life of piroxicam. It may be concluded from these results that absorption, elimination and bioavailability kinetics of droxicam are independent of the administered dose.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2633925     DOI: 10.1007/BF03190116

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  16 in total

1.  Pharmacokinetics of droxicam in rat and dog.

Authors:  A Esteve; L Martínez; R Roser; R Sagarra
Journal:  Methods Find Exp Clin Pharmacol       Date:  1986-07

2.  Comparative study of the multiple dose pharmacokinetics and the tolerance of a new NSAID (droxicam) versus piroxicam in healthy volunteers.

Authors:  L Martínez; J Sánchez; R Roser; J García-Barbal; A Bartlett; J Estruch; R Sagarra; S Puig; A Costa
Journal:  Methods Find Exp Clin Pharmacol       Date:  1988-11

3.  Safety of piroxicam.

Authors:  S M Wolfe
Journal:  Lancet       Date:  1986-10-04       Impact factor: 79.321

4.  [Pharmacokinetic study of piroxicam in healthy man after administration of a single dose equal to 20 mg, by the oral route].

Authors:  J B Fourtillan; D Dubourg
Journal:  Therapie       Date:  1983 Mar-Apr       Impact factor: 2.070

5.  Analysis of piroxicam in plasma by high-performance liquid chromatography.

Authors:  T M Twomey; S R Bartolucci; D C Hobbs
Journal:  J Chromatogr       Date:  1980-07-11

6.  Effects of droxicam on in vivo prostaglandin synthesis and ex vivo platelet aggregation.

Authors:  J Esteve; L Martínez; R Roser; R Sagarra
Journal:  Methods Find Exp Clin Pharmacol       Date:  1987-04

7.  The influence of gastric emptying on droxicam pharmacokinetics.

Authors:  J Sánchez; L Martínez; J García-Barbal; R Roser; A Bartlett; R Sagarra
Journal:  J Clin Pharmacol       Date:  1989-08       Impact factor: 3.126

8.  Piroxicam pharmacokinetics in man: aspirin and antacid interaction studies.

Authors:  D C Hobbs; T M Twomey
Journal:  J Clin Pharmacol       Date:  1979 May-Jun       Impact factor: 3.126

9.  Pharmacological properties of droxicam, a new non-steroidal anti-inflammatory agent.

Authors:  A J Farré; M Colombo; M Fort; B Gutiérrez; L Rodríguez; R Roser
Journal:  Methods Find Exp Clin Pharmacol       Date:  1986-07

Review 10.  Piroxicam: a review of its pharmacological properties and therapeutic efficacy.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1981-09       Impact factor: 9.546

View more
  3 in total

1.  A comparative bioavailability study to estimate the influence of an antacid on droxicam pharmacokinetics.

Authors:  M T Maya; J P Pais; J Ruas Da Silva; J A Morais
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1995 Oct-Dec       Impact factor: 2.441

Review 2.  Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents.

Authors:  K T Olkkola; A V Brunetto; M J Mattila
Journal:  Clin Pharmacokinet       Date:  1994-02       Impact factor: 6.447

3.  Cross-over study of the bioavailability of a new NSAID (droxicam) versus piroxicam in healthy volunteers following single and multiple dose administration.

Authors:  A Bartlett; A Costa; L Martinez; R Roser; R Sagarra; J Sanchez
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Jul-Sep       Impact factor: 2.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.